These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 26153511)

  • 1. Similar chemokine receptor profiles in lymphomas with central nervous system involvement - possible biomarkers for patient selection for central nervous system prophylaxis, a retrospective study.
    Lemma SA; Pasanen AK; Haapasaari KM; Sippola A; Sormunen R; Soini Y; Jantunen E; Koivunen P; Salokorpi N; Bloigu R; Turpeenniemi-Hujanen T; Kuittinen O
    Eur J Haematol; 2016 May; 96(5):492-501. PubMed ID: 26153511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrin alpha 10, CD44, PTEN, cadherin-11 and lactoferrin expressions are potential biomarkers for selecting patients in need of central nervous system prophylaxis in diffuse large B-cell lymphoma.
    Lemma SA; Kuusisto M; Haapasaari KM; Sormunen R; Lehtinen T; Klaavuniemi T; Eray M; Jantunen E; Soini Y; Vasala K; Böhm J; Salokorpi N; Koivunen P; Karihtala P; Vuoristo J; Turpeenniemi-Hujanen T; Kuittinen O
    Carcinogenesis; 2017 Aug; 38(8):812-820. PubMed ID: 28854563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preferential up-regulation of osteopontin in primary central nervous system lymphoma does not correlate with putative receptor CD44v6 or CD44H expression.
    Yuan J; Gu K; He J; Sharma S
    Hum Pathol; 2013 Apr; 44(4):606-11. PubMed ID: 23089492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central nervous system prophylaxis in diffuse large B-cell lymphoma.
    Zahid MF; Khan N; Hashmi SK; Kizilbash SH; Barta SK
    Eur J Haematol; 2016 Aug; 97(2):108-20. PubMed ID: 27096423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metallothionein-I + II and receptor megalin are altered in relation to oxidative stress in cerebral lymphomas.
    Pedersen MØ; Hansen PB; Nielsen SL; Penkowa M
    Leuk Lymphoma; 2010 Feb; 51(2):314-28. PubMed ID: 20038220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role and application of chemokine CXCL13 in central nervous system lymphoma.
    Li C; Zhang L; Jin Q; Jiang H; Wu C
    Ann Hematol; 2024 Aug; 103(8):2671-2680. PubMed ID: 38010409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression pattern and cellular sources of chemokines in primary central nervous system lymphoma.
    Brunn A; Montesinos-Rongen M; Strack A; Reifenberger G; Mawrin C; Schaller C; Deckert M
    Acta Neuropathol; 2007 Sep; 114(3):271-6. PubMed ID: 17641901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secondary central nervous system (CNS) involvement in patients with diffuse large B-cell lymphoma: a therapeutic dilemma.
    Kim SJ; Oh SY; Kim JS; Kim H; Lee GW; Won JH; Shin HJ; Yang DH; Choi CW; Park J; Kim WS; Suh C
    Ann Hematol; 2011 May; 90(5):539-46. PubMed ID: 20960190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Central nervous system relapse in diffuse large B cell lymphoma: Risk factors].
    Sancho JM; Ribera JM;
    Med Clin (Barc); 2016 Jan; 146(2):74-80. PubMed ID: 25817451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature.
    Guirguis HR; Cheung MC; Mahrous M; Piliotis E; Berinstein N; Imrie KR; Zhang L; Buckstein R
    Br J Haematol; 2012 Oct; 159(1):39-49. PubMed ID: 22849793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab.
    Tai WM; Chung J; Tang PL; Koo YX; Hou X; Tay KW; Quek R; Tao M; Lim ST
    Ann Hematol; 2011 Jul; 90(7):809-18. PubMed ID: 21229246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary Intra-Axial Diffuse Large B-Cell Lymphoma in Immunocompetent Patients: Clinical Impact of Molecular Analysis and Histogenetic Evaluation.
    Cambruzzi E
    World Neurosurg; 2020 Feb; 134():215-220. PubMed ID: 31605845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of B-cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma.
    Smith JR; Braziel RM; Paoletti S; Lipp M; Uguccioni M; Rosenbaum JT
    Blood; 2003 Feb; 101(3):815-21. PubMed ID: 12393412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Isolated central nervous system relapse of diffuse large B-cell lymphoma in the era of immunochemotherapy].
    Krmek DZ; Ljubić N; Vrbanić L
    Acta Med Croatica; 2012 Dec; 66(5):403-7. PubMed ID: 23814970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diffuse large B-cell lymphoma involving the central nervous system: biologic rationale for targeted therapy.
    Roschewski M; Hodson DJ
    Haematologica; 2024 Feb; 109(2):388-400. PubMed ID: 37706315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance status, comorbidities, and cycles of methotrexate exert the greatest influence on outcomes of primary and secondary CNS lymphomas: the Lexington experience.
    Curry LD; Munker R; Li N; Yan D; Pryor P; Nozad S; Keller P; Monohan GP; Iragavarapu C; Krem MM
    Ann Hematol; 2023 Jan; 102(1):141-154. PubMed ID: 36367559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era.
    Ferreri AJ; Bruno-Ventre M; Donadoni G; Ponzoni M; Citterio G; Foppoli M; Vignati A; Scarfò L; Sassone M; Govi S; Caligaris-Cappio F
    Br J Haematol; 2015 Mar; 168(5):654-62. PubMed ID: 25312994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Array-based profiling of the lymphoma cell DNA methylome does not unequivocally distinguish primary lymphomas of the central nervous system from non-CNS diffuse large B-cell lymphomas.
    Vogt J; Wagener R; Montesinos-Rongen M; Ammerpohl O; Paulus W; Deckert M; Siebert R
    Genes Chromosomes Cancer; 2019 Jan; 58(1):66-69. PubMed ID: 30284345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma.
    Abramson JS; Hellmann M; Barnes JA; Hammerman P; Toomey C; Takvorian T; Muzikansky A; Hochberg EP
    Cancer; 2010 Sep; 116(18):4283-90. PubMed ID: 20564149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-30c as a novel diagnostic biomarker for primary and secondary B-cell lymphoma of the CNS.
    Baraniskin A; Chomiak M; Ahle G; Gress T; Buchholz M; Turewicz M; Eisenacher M; Margold M; Schlegel U; Schmiegel W; Hahn S; Schroers R
    J Neurooncol; 2018 May; 137(3):463-468. PubMed ID: 29327175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.